Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Large Decline in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 9,927 shares, a drop of 85.3% from the June 30th total of 67,330 shares. Based on an average trading volume of 18,424 shares, the short-interest ratio is currently 0.5 days. Approximately 0.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up approximately 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest position. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Trading Down 1.8%

NASDAQ BDRX traded down $0.03 during mid-day trading on Friday, hitting $1.65. The company’s stock had a trading volume of 63,546 shares, compared to its average volume of 412,269. The stock’s fifty day simple moving average is $2.84 and its two-hundred day simple moving average is $4.82. Biodexa Pharmaceuticals has a 52-week low of $1.64 and a 52-week high of $59.40.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BDRX shares. Weiss Ratings raised Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. Wall Street Zen cut Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.